Metabolic & Cardiometabolic
GLP-1 receptor agonists improves MASH / NASH (steatohepatitis)
In plain terms: Can GLP-1 drugs help fatty-liver disease (MASH/NASH), including the scarring?
Strong support Metabolic & Cardiometabolic
Part of: 💊 GLP-1 Drugs
RefutedContestedStrong support
consensus score 0.81
Yes for resolving the inflammation — robustly shown for semaglutide and tirzepatide; the harder fibrosis (scarring) benefit was null in early phase-2 but reached significance in the large phase-3 ESSENCE trial.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
9 support 0 contradict 0 tested null 2 mixed · 11 sources, 9 independent groups · 2 superseded — pooled inside a review, counted once
The evidence (29)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Alzaki 2026 · Cureus | RCT | supports | high | Across seven biopsy-confirmed MASH RCTs, GLP-1 (semaglutide) and GIP/GLP-1 (tirzepatide) agonists improved histologic MASH resolution, with semaglutide achieving dual endpoints in phase 3 ESSENCE. |
| Suresh MG et al 2026 · study_type: observational | observational | supports | low | Narrative review of MASLD/T2DM: GLP-1 receptor agonists (among other antidiabetic agents) show hepatic benefits beyond glycemic control as part of emerging pharmacotherapy landscape. |
| Khalifa O et al 2026 · study_type: observational | observational | supports | moderate | Comprehensive narrative review from GLP-1 discovery to FDA approval: extensive mechanistic, preclinical, and clinical evidence show GLP-1RAs reduce hepatic steatosis, attenuate inflammation, and impede disease progression, established as th |
| Armstrong 2016 · Lancet | RCT | supports | moderate | LEAN phase-2: liraglutide steatohepatitis resolution 39% vs 9% placebo with no fibrosis worsening; small (n=52). ↩ SUPERSEDED — pooled in the review above, counted once |
| Sun 2024 · Drugs | meta-analysis | supports | moderate | 24-wk NAFLD NMA: GLP-1RA improve hepatic steatosis/enzymes vs placebo; shorter horizon limits fibrosis read. |
| Tang M et al 2026 · study_type: meta-analysis | meta-analysis | supports | high | Frequentist network meta-analysis of 34 studies/33 RCTs (Phase II/III, biopsy-proven MASH): GLP-1/GIP dual agonists had the highest MASH-resolution efficacy (RR 5.21) and GLP-1 RAs alone improved fibrosis (RR 1.51, 95% CI 1.09-2.10) versus |
| Malandris K et al 2026 · study_type: observational | observational | supports | low | Narrative review: GLP-1 RAs and dual GIP/GLP-1 RAs demonstrate 'meaningful benefits' in steatohepatitis; semaglutide provides the most robust evidence for fibrosis benefit, with potential antifibrotic effects also for tirzepatide. |
| McGuire 2025 · N Engl J Med | RCT | supports | low | SOUL (CV trial) supports systemic cardiometabolic benefit relevant to liver-heart axis; not a liver-histology endpoint. |
| Newsome 2021 · N Engl J Med | RCT | mixed | moderate | Authors' reply reaffirming phase-2 result: strong NASH resolution, fibrosis endpoint not met — honest limitation. |
| Weng J et al 2026 · study_type: observational | observational | supports | low | Retrospective cohort (n=229 MASLD patients on GLP-1 RAs, 29 with baseline FIB-4≥1.3): mean FIB-4 decreased from 1.94 to 1.73 over 12 months (95% CI -0.38 to -0.05, P=0.019), with significant AST/ALT/BMI/A1c reductions; FIB-4 improvement ind |
| Lin RT et al] # corrected 2026-08-17 from PubMed; was [Zhou 2024 · Metabolism | meta-analysis | mixed | high | NMA of MASLD drugs: GLP-1RA and polyagonists improve histology/resolution; THR-beta/FGF21 stronger for fibrosis specifically. |
| Newsome 2025 · N Engl J Med | RCT | supports | high | ESSENCE phase-3 (240wk): semaglutide 2.4mg — steatohepatitis resolution 62.9% vs 34.3% AND fibrosis improvement 36.8% vs 22.4% (both P<0.001). |
| Mahoon D et al 2026 · study_type: meta-analysis | RCT | supports | moderate | Systematic review (PROSPERO CRD420261337353) of 12 studies: GLP-1RAs (semaglutide, liraglutide, dulaglutide, beinaglutide) most consistently reduced hepatic fat, with strongest histological benefit for steatohepatitis resolution in non-cirr |
| Tsakiridis EE et al 2026 · study_type: mechanism | observational | supports | moderate | Mechanistic review: GLP-1-based therapies consistently improve steatosis and steatohepatitis via reduced hepatic nutrient flux, improved adipose insulin sensitivity, and weight-independent anti-inflammatory effects, despite limited direct h |
| Loomba 2024 · N Engl J Med | RCT | supports | high | SYNERGY-NASH: tirzepatide MASH resolution 44-62% vs 10% placebo (dose-dependent, P<0.001); fibrosis signals favorable. ↩ SUPERSEDED — pooled in the review above, counted once |
| Dos Santos Borges R et al] # corrected 2026-08-17 from PubMed; was [2026 venue: JHEP Rep · JHEP Rep | meta-analysis | supports | high | SR/MA of GLP-1RA in MASH w/ fibrosis: consistent steatohepatitis resolution; pooled fibrosis benefit now emerging. |
| Abenavoli L et al 2026 · study_type: observational | observational | supports | low | Narrative review: GLP-1 receptor agonists reduce hepatic steatosis, inflammation, and fibrosis-related biomarkers, primarily via weight loss and improved insulin sensitivity; dual GLP-1/GIP agonists (tirzepatide) show superior outcomes; fib |
| Damen 2026 · Ann Intern Med | meta-analysis | supports | low | The prior extract ('improves obesity-linked steatotic liver disease markers') has NO basis in this paper - the strings liver, hepat, steato, MASH and NASH return zero hits across the whole record. The review's stated scope is 'pharmacologic treatments for weight management in overweight or obesity in adults' for 'outcomes such as mortality, weight loss, and quality of life', and its results sentence is 'Semaglutide probably reduced mortality and major adverse cardiovascular events (MACE), and both semaglutide and tirzepatide led to the greatest weight loss compared with placebo and/or LI in pairwise and network meta-analyses.' OFF-SCOPE: wrong outcome. Quality dropped to low as this source carries no information on the claim at all. Read from abstract only (2026-08-19). |
| Tornea DA et al 2026 · study_type: meta-analysis | meta-analysis | supports | high | Systematic review and meta-analysis of 20 RCTs: GLP-1 agonists significantly increased MASH resolution without fibrosis worsening (RR 3.03, p<0.0001) and fibrosis improvement by ≥1 stage (RR 1.45, p<0.00001) overall, but in patients without |
| Pantea I et al 2026 · study_type: observational | observational | supports | moderate | Bibliometric + evidence review of tirzepatide: SYNERGY-NASH trial showed high rates of MASH resolution without fibrosis worsening and 'meaningful fibrosis regression' at 52 weeks; EASL-EASD-EASO guidelines recommend tirzepatide for MASLD wi |
| Amorim 2026 · Chronic Dis Transl Med | observational | supports | moderate | Review: liraglutide (LEAN), semaglutide (phase-2/ESSENCE), tirzepatide (SYNERGY) all improve MASH; durability of fibrosis benefit a gap. |
| Dinkov B et al 2026 · study_type: observational | observational | supports | moderate | Narrative review (33 studies): tirzepatide achieved MASH resolution in 44-62% of patients in phase 2 SYNERGY-NASH; semaglutide FDA-approved for MASH with fibrosis based on Phase 3 ESSENCE trial; preclinical data show gut-microbiome-mediated |
| Zacharia GS et al 2025 · study_type: observational | observational | supports | moderate | Narrative review: semaglutide therapy is associated with resolution of steatohepatitis and improvement in hepatic fibrosis; approved (with resmetirom) for non-cirrhotic MASH with moderate-to-advanced fibrosis. |
| Choi S et al 2026 · study_type: mechanism | observational | supports | low | Mechanistic review proposing an AMPK-centric framework for MASH therapeutics: GLP-1 receptor agonists (e.g., semaglutide) are framed as acting predominantly through systemic effects (weight loss, glycemic control) converging on AMPK activat |
| Mahalingam S et al 2026 · study_type: observational | observational | supports | low | Narrative review: GLP-1 RAs' efficacy in resolving MASH is 'increasingly well documented,' via weight loss, improved insulin sensitivity, reduced hepatic lipogenesis, and anti-inflammatory/AMPK-mediated effects; extension to ALD/MetALD and |
| Wang MJ et al 2026 · study_type: meta-analysis | meta-analysis | supports | high | PRISMA systematic review + meta-analysis of 25 RCTs (n=2481): GLP-1 RAs significantly increased MASH resolution without fibrosis worsening (OR 4.04, 95% CI 2.69-6.05, high GRADE certainty) but showed no significant fibrosis improvement (OR |
| Newsome 2021 · N Engl J Med | RCT | supports | high | Phase-2, 72-week, double-blind, placebo-controlled, biopsy-confirmed NASH (n=320; NCT02970942, Novo Nordisk). Primary endpoint, the claim's own outcome: 'The percentage of patients in whom NASH resolution was achieved with no worsening of fibrosis was 40% in the 0.1-mg group, 36% in the 0.2-mg group, 59% in the 0.4-mg group, and 17% in the placebo group (P<0.001 for semaglutide 0.4 mg vs. placebo).' The trial's fibrosis-stage null (43% vs 33%, P=0.48) is a DIFFERENT outcome from this claim's steatohepatitis object and is logged as a candidate for a fibrosis claim, not folded in here. Limits: only the top of three doses was formally significant, dose-response non-monotonic, endpoint analysis restricted to the 230 F2/F3 patients. |
| Villaseñor-Tapia EC et al 2026 · study_type: observational | observational | supports | low | Narrative review: GLP-1 receptor agonists show 'clinically meaningful improvements' in metabolic parameters and hepatic steatosis, though impact on fibrosis and long-term disease modification remains uncertain. |
| Cruz AM et al 2026 · study_type: meta-analysis | RCT | supports | high | Systematic review of clinical studies: semaglutide phase 3 achieved MASH resolution w/o fibrosis worsening in 62.9% vs 34.3% placebo (p<0.001); phase 2 NASH resolution 59% vs 17% (p<0.001) but no significant fibrosis improvement (43% vs 33% |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.